日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial

稳定期多发性硬化症患者停止一线疾病修饰疗法:DOT-MS随机临床试验

Coerver, Eline M E; Fung, Wing Hee; de Beukelaar, Janet; Bouvy, Willem H; Canta, Leo R; Gerlach, Oliver H H; Hoitsma, Elske; Hoogervorst, Erwin L J; de Jong, Brigit A; Kalkers, Nynke F; van Kempen, Zoé L E; Lövenich, Harry; van Munster, Caspar E P; van Oosten, Bob W; Smolders, Joost; Vennegoor, Anke; Zeinstra, Esther M P E; Barrantes-Cepas, Mar; Kooij, Gijs; Schoonheim, Menno M; Lissenberg-Witte, Birgit I; Teunissen, Charlotte E; Moraal, Bastiaan; Barkhof, Frederik; Uitdehaag, Bernard M J; Mostert, Jop; Killestein, Joep; Strijbis, Eva M M

Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

血清神经丝轻链和胶质纤维酸性蛋白在稳定期多发性硬化症患者停用一线疾病修饰疗法后检测疾病活动的可靠性(DOT-MS)

Fung, W H; Wessels, M H J; Coerver, E M E; de Beukelaar, J; Bouvy, W H; Canta, L R; Gerlach, O H H; Hoitsma, E; Hoogervorst, E L J; de Jong, B A; Kalkers, N F; van Kempen, Z L E; Lövenich, H; van Munster, C E P; van Oosten, B W; Smolders, J; Vennegoor, A; Zeinstra, E M P E; Barrantes-Cepas, M; Kooij, G; Schoonheim, M M; Lissenberg-Witte, B I; Moraal, B; Barkhof, F; Uitdehaag, B M J; Mostert, J; Teunissen, C E; Killestein, J; Strijbis, E M M

Mechanistic Understanding of Protein-MOF Integration through Surfactant-Driven Interfacial Design

通过表面活性剂驱动的界面设计,深入理解蛋白质-MOF整合的机制

Rashidniyaghi, Ehsan; Khavani, Mohammad; Coerver, Carlie; Liang, Ruibin; Ravanfar, Raheleh

Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations

在复发型多发性硬化症试验人群中,衰老与炎症性疾病活动性降低相关,且与疾病持续时间无关。

Coerver, Eline Me; Kaçar, Sezgi; Ciccarelli, Olga; Sormani, Maria P; Barkhof, Frederik; Arnold, Douglas L; Schoonheim, Menno M; Van Kempen, Zoé LE; Mostert, Jop; Koch, Marcus W; Killestein, Joep; Eshaghi, Arman; Uitdehaag, Bernard Mj; Strijbis, Eva Mm

Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology

抗淀粉样蛋白单克隆抗体疗法治疗阿尔茨海默病:神经病学领域的新问题

Ramanan, Vijay K; Armstrong, Melissa J; Choudhury, Parichita; Coerver, Katherine A; Hamilton, Roy H; Klein, Brad C; Wolk, David A; Wessels, Scott R; Jones, Lyell K Jr

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee

阿杜卡奴单抗在症状性阿尔茨海默病中的应用:证据聚焦[已撤稿]:美国神经病学会指南小组委员会报告

Day, Gregory S; Scarmeas, Nikolaos; Dubinsky, Richard; Coerver, Katherine; Mostacero, Anitra; West, Brooks; Wessels, Scott R; Armstrong, Melissa J

Practical Considerations in the Administration of Aducanumab for the Neurologist

神经科医生在使用阿杜卡奴单抗治疗时需要考虑的实际问题

Coerver, Katherine; Yu, Melissa M; D'Abreu, Anelyssa; Wasserman, Marc; Nair, Kavita V

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis

血液中 MxA mRNA 与早期多发性硬化症长期疾病活动性之间的关联

Coerver, Eline M E; Strijbis, Eva M M; Petzold, Laura F; Van Kempen, Zoé L E; Jasperse, Bas; Barkhof, Frederik; Oudejans, Cees B M; Uitdehaag, Bernard M J; Teunissen, Charlotte E; Killestein, Joep

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

在JC病毒阳性复发缓解型多发性硬化症患者中,奥瑞珠单抗治疗后接受那他珠单抗治疗

van Lierop, Zygj; Toorop, A A; Coerver, Eme; Willemse, Eaj; Strijbis, Emm; Kalkers, N F; Moraal, B; Barkhof, F; Teunissen, C E; Killestein, J; van Kempen, Zle